Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cosmos Health Inc
(NQ:
COSM
)
1.400
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cosmos Health Inc
< Previous
1
2
3
4
Next >
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
July 10, 2024
Via
ACCESSWIRE
Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually
July 09, 2024
Via
ACCESSWIRE
Cosmos Health Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months
July 02, 2024
Via
ACCESSWIRE
Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE
July 02, 2024
Via
ACCESSWIRE
Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains
July 01, 2024
Via
ACCESSWIRE
Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units
June 27, 2024
Via
ACCESSWIRE
Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent
June 18, 2024
Via
ACCESSWIRE
Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million
June 13, 2024
Via
ACCESSWIRE
Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q
May 24, 2024
Via
ACCESSWIRE
Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand
May 17, 2024
Via
ACCESSWIRE
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
April 19, 2024
Via
ACCESSWIRE
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
March 21, 2024
Via
ACCESSWIRE
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
March 19, 2024
Via
ACCESSWIRE
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
March 18, 2024
Via
ACCESSWIRE
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
February 29, 2024
Via
ACCESSWIRE
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
February 21, 2024
Via
ACCESSWIRE
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
February 20, 2024
Via
ACCESSWIRE
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
February 01, 2024
Via
ACCESSWIRE
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
January 23, 2024
Via
ACCESSWIRE
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
January 18, 2024
Via
ACCESSWIRE
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
December 27, 2023
Via
ACCESSWIRE
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
December 20, 2023
Via
ACCESSWIRE
Cosmos Health Announces Open Market Stock Purchases by the CEO
December 18, 2023
Via
ACCESSWIRE
Cosmos Health to Participate at Capital Link’s 'Invest in Greece' Forum in New York
December 08, 2023
Via
ACCESSWIRE
Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers
December 07, 2023
Via
ACCESSWIRE
Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product
December 01, 2023
Via
ACCESSWIRE
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
November 21, 2023
Via
ACCESSWIRE
Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders
October 11, 2023
Via
ACCESSWIRE
COSMOS HEALTH CEO Issues Letter to Shareholders
October 05, 2023
Via
ACCESSWIRE
Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company
September 27, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.